Item 2.03 Creation of a Direct Financial Obligation or an Obligation
under an Off-Balance Sheet Arrangement of a Registrant.
As previously disclosed, Verastem, Inc. (the “Company”)
entered into a loan and security agreement (the “Loan Agreement”), dated March 25, 2022 (the “Closing Date”),
with Oxford Finance LLC (“Oxford”), as collateral agent and a lender, and Oxford Finance Credit Fund III LP, as a lender
(together with Oxford, the “Lenders”), pursuant to which the Lenders have agreed to lend the Company up to an aggregate principal
amount of $150.0 million in a series of term loans (the “Term Loans”), of which $50.0 million is subject to the Lenders’
sole discretion.
Pursuant to the Loan Agreement, the Company received an initial Term
Loan of $25.0 million on the Closing Date, leaving an additional $125.0 million of Term Loans available to borrow, subject to conditions
specified in the Loan Agreement. One of the series of Terms Loans is a $15.0 million Term B Loan (the “Term B Loan”), which
may be drawn upon only when the Company has either (a) received the Regulatory Milestone Payment (as defined in the Asset Purchase
Agreement between the Company and Secura Bio, Inc., dated August 10, 2020) from Secura Bio, Inc. of $35.0 million which
is due upon receipt of regulatory approval of COPIKTRA in the United States for the treatment of peripheral T-cell lymphoma or (b) received
at least $50.0 million in unrestricted cash proceeds from the sale or issuance of equity securities after the Closing Date (the “Term
B Milestones”).
On March 22,
2023, the Company elected to draw down the $15.0 million Term B Loan, having received at least $50.0 million in unrestricted cash
proceeds from the sale or issuance of equity securities.
As previously disclosed, the Term Loans bear interest at a floating
rate equal to (a) the greater of (i) the one-month CME Secured Overnight Financing Rate and (ii) 0.13% plus (b) 7.37%,
which is subject to an overall floor and cap. Interest is payable monthly in arrears on the first calendar day of each calendar month.
As a result of the Term B Loan drawdown, beginning April 1, 2025,
the Company shall repay the outstanding principal under the Term Loans in consecutive equal monthly payments of principal, together with
applicable interest, in arrears. All unpaid principal and accrued and unpaid interest with respect to each Term Loan is due and payable
in full on March 1, 2027.
The Company will be required to make a final payment of 5.0% of the
original principal amount of the Term Loans that were drawn, payable at maturity or upon any earlier acceleration or prepayment of the
Term Loans. The Company may prepay all, but not less than all, of the Term Loans, subject to a prepayment fee equal to (i) 3.0% of
the principal amount of the applicable Term Loan if prepaid on or before the first anniversary date of the funding date of such Term Loan,
(ii) 2.0% of the principal amount of the applicable Term Loan if prepaid after the first anniversary and on or before the second
anniversary of the funding date of such Term Loan, and (iii) 1.0% of the principal amount of the applicable Term Loan if prepaid
after the second anniversary of the applicable funding date of such Term Loan. All Term Loans will be subject to a facility fee of 0.5%
of the principal amount.
The Loan Agreement contains no financial covenants. The Loan Agreement
includes customary events of default, including, among others, payment defaults, breach of representations and warrants, covenant defaults,
judgment defaults, insolvency and bankruptcy defaults, and a material adverse change. The occurrence of an event of default could result
in the acceleration of the obligations under the Loan Agreement, termination of the Term Loan commitments and the right to foreclose on
the collateral securing the obligations. During the existence of an event of default, the Term Loans will accrue interest at a rate per
annum equal to 5.00% above the otherwise applicable interest rate.
The foregoing description of the Loan Agreement does not purport to
be complete and is qualified in its entirety by reference to the full text of the Loan Agreement which was filed as Exhibit 10.1
to the Current Report on Form 8-K filed by the Company on March 28, 2022.